✓ No loaded language, vague sourcing, or framing detected.
A Tufts Center study reveals that AI can significantly improve the efficiency of clinical trials for cancer treatments, potentially reducing trial time by 10 weeks and costs by up to $5.6 million. The technology may become standard in trials within three to five years, although challenges in patient recruitment and consent persist.
Our neutral summary
A Tufts Center study reveals that AI can significantly improve the efficiency of clinical trials for cancer treatments, potentially reducing trial time by 10 weeks and costs by up to $5.6 million. The technology may become standard in trials within three to five years, although challenges in patient recruitment and consent persist.
The reporting belongs to Axios; we don't reproduce it.
No note attached
on this article.
AI brings savings to clinical trials: study
Study finds AI can improve efficiency in clinical trials for cancer treatments